<?xml version="1.0" encoding="UTF-8"?>
<p id="para390">The safety profile of the MARIETTA programme could be considered to be favourable compared with that reported in the SCNSL1 trial, which consisted of an intensified strategy associated with grade 3â€“4 infections or febrile neutropenia in 24% of delivered courses (compared with 13% in the MARIETTA trial; 
 <xref rid="sec1" ref-type="sec">appendix p 10</xref>) and 11% treatment-related mortality (compared with 5% in the MARIETTA trial). Importantly, intensification high-dose sequential chemoimmunotherapy of the SCNSL1 trial is used only in selected centres in Italy, whereas MATRix and RICE are two standardised regimens that are used in routine practice in several countries. A study from June, 2020,
 <xref rid="bib22" ref-type="bibr">
  <sup>22</sup>
 </xref> shows that MATRix is used in routine practice in many cancer centres with similar activity and tolerability to that reported within prospective trials.
 <xref rid="bib13" ref-type="bibr">
  <sup>13</sup>
 </xref>
</p>
